21 terminated. 21 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 21 | Terminated 21 |
| Phase 2 | 3 | Terminated 3 |
Follow Glomerulonephritis: new trials by email Literature Review of Glomerulonephritis trials Research Report on Glomerulonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis voclosporin - Adolescent Lupus Nephritis, Pediatric Lupus Nephritis | Phase 3 | Terminated | Aurinia Pharmaceuticals Inc. | 4 | 2024-03-28 | 2026-02-10 |
| Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis Voclosporin, Placebo Oral Capsule - Adolescent Lupus Nephritis, Pediatric Lupus Nephritis | Phase 3 | Terminated | Aurinia Pharmaceuticals Inc. | 9 | 2023-10-10 | 2026-02-10 |
| A Study With Imlifidase in Anti-GBM Disease Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC) - Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease | Phase 3 | Terminated | Hansa Biopharma AB | 50 | 2022-12-22 | 2026-03-04 |
| Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis Secukinumab - Lupus Nephritis | Phase 3 | Terminated | Novartis Pharmaceuticals | 31 | 2022-08-22 | 2025-05-16 |
| Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN Rituximab, cyclosporine - Idiopathic Membranous Nephropathy | Phase 3 | Terminated | Peking Union Medical College Hospital | 12 | 2021-04-14 | 2025-12-09 |
| Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis secukinumab, Placebo - Lupus Nephritis | Phase 3 | Terminated | Novartis Pharmaceuticals | 275 | 2020-07-07 | 2025-05-16 |
| Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy OMS721, Vehicle (D5W or saline) - IgA Nephropathy | Phase 3 | Terminated | Omeros Corporation | 360 | 2018-04-05 | 2025-12-09 |
| Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy Plasma Exchange (PE), Methylprednisolone pulse - Glomerulonephritis, IGA, Kidney Diseases | Phase 2 / Phase 3 | Terminated | Peking University First Hospital | 10 | 2016-03-01 | 2021-10-08 |
| Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis Oral prednisolone, Rituximab, Mycophenolate mofetil - Systemic Lupus Erythematosus, Lupus Nephritis | Phase 3 | Terminated | Imperial College London | 24 | 2015-04-01 | 2018-02-01 |
| Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis BMS-188667, Mycophenolate mofetil, Prednisone - Lupus Nephritis | Phase 3 | Terminated | Bristol-Myers Squibb | 695 | 2013-01-22 | 2021-02-26 |
| Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy Rituximab - Lupus Nephritis | Phase 3 | Terminated | Fundación Pública Andaluza Progreso y Salud | 9 | 2012-11-01 | 2015-07-10 |
| A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients tacrolimus capsule, tacrolimus placebo, leflunomide tablet - Lupus Nephritis | Phase 3 | Terminated | Astellas Pharma Inc | 84 | 2011-04-01 | 2014-10-17 |
| The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis mycophenolate sodium, cyclophosphamide - Lupus Nephritis | Phase 3 | Terminated | Chulalongkorn University | 59 | 2010-01-01 | 2014-10-10 |
| A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG) Corticosteroids, Cyclophosphamide, Mycophenolate Mofetil - Lupus Nephritis, Systemic Lupus Erythematosus | Phase 3 | Terminated | Genentech, Inc. | 381 | 2008-02-15 | 2020-12-22 |
| The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis Atacicept, Mycophenolate mofetil, Placebo - Lupus Nephritis | Phase 2 / Phase 3 | Terminated | EMD Serono | 6 | 2007-12-01 | 2016-03-23 |
| A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis. Mycophenolate Mofetil, Corticosteroids, Azathioprine - Lupus Nephritis | Phase 3 | Terminated | Hoffmann-La Roche | 52 | 2007-03-01 | 2014-09-25 |
| TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ) infliximab, placebo - Lupus Erythematosus, Systemic, Lupus Nephritis | Phase 2 / Phase 3 | Terminated | Medical University of Vienna | 1 | 2006-09-01 | 2009-10-05 |
| Efficacy of Pentoxifylline on Rapidly Progressive Glomerulonephritis pentoxifylline, corticosteroids - Glomerulonephritis | Phase 3 | Terminated | National Taiwan University Hospital | 7 | 2006-08-01 | 2012-11-14 |
| A Study to Evaluate Efficacy of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis Mycophenolate mofetil (MMF), Cyclophosphamide, Maintenance Phase, Cyclophosphamide, Induction Phase - Lupus Nephritis | Phase 3 | Terminated | Hoffmann-La Roche | 16 | 2006-03-01 | 2014-07-17 |
| Study of LJP 394 in Lupus Patients With History of Renal Disease abetimus sodium (LJP 394) and/or placebo solution, abetimus sodium (LJP 394), Phosphate-buffered saline - Lupus Erythematosus, Systemic, Lupus Nephritis | Phase 3 | Terminated | La Jolla Pharmaceutical Company | 943 | 2004-10-01 | 2009-04-01 |
Showing 20 of 21. Sign in to see all of them.
Lupus Nephritis (15) · Lupus Erythematosus, Systemic (5) · Nephritis (5) · Glomerulonephritis, IGA (3) · Proteinuria (3) · Acute Kidney Injury (1) · Anti-Glomerular Basement Membrane Disease (1) · Glomerulonephritis, Membranous (1) · Kidney Diseases (1) · Rapidly progressive glomerulonephritis with pulmonary hemorrhage (1) · Renal Insufficiency, Chronic (1)
Female Urogenital Diseases (21) · Female Urogenital Diseases and Pregnancy Complications (21) · Male Urogenital Diseases (21) · Urogenital Diseases (21) · Urologic Diseases (21) · Autoimmune Diseases (20) · Immune System Diseases (20) · Kidney Diseases (20) · Nephritis (16) · Connective Tissue Diseases (15) · Skin and Connective Tissue Diseases (15) · Lupus Erythematosus, Systemic (10) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3)
Mycophenolic Acid (8) · Cyclophosphamide (5) · Adrenal Cortex Hormones (4) · Prednisone (3) · Rituximab (3) · Azathioprine (2) · Plasma Exchange (2) · Prednisolone (2) · secukinumab (2) · voclosporin (2) · Abatacept (1) · Angiotensin-Converting Enzyme Inhibitors (1) · Cyclosporine (1) · Glucocorticoids (1) · Infliximab (1)
Aurinia Pharmaceuticals Inc. (2) · Hoffmann-La Roche (2) · Novartis Pharmaceuticals (2) · Astellas Pharma Inc (1) · Bristol-Myers Squibb (1) · Chulalongkorn University (1) · EMD Serono (1) · Fundación Pública Andaluza Progreso y Salud (1) · Genentech, Inc. (1) · Hansa Biopharma AB (1) · Imperial College London (1) · La Jolla Pharmaceutical Company (1) · Medical University of Vienna (1) · National Taiwan University Hospital (1) · Omeros Corporation (1)
United States (9) · Czechia (7) · Spain (7) · Thailand (7) · China (6) · Taiwan (6) · Australia (5) · Colombia (5) · Germany (5) · Italy (5) · Japan (5) · Mexico (5) · South Korea (5) · Argentina (4) · Brazil (4)
Falk Hiepe, MD (1) · Hong Zhang, MD, PHD (1) · Josef S Smolen, MD (1) · Liz Lightstone, Dr (1) · Marc Bijl, MD (1) · Martin Aringer, MD (1) · Michael J Tansey, MD, Ph.D. (1) · Ronald J Hogg, M.D. (1)
PMID 38299639, PMID 41092316, PMID 22325903, PMID 26835147, PMID 35675911, PMID 37528520, PMID 37772889, PMID 38864363, PMID 41241398
2019 (1)